Welcome to our dedicated page for Akari Therapeutics, Plc news (Ticker: $AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics, Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akari Therapeutics, Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akari Therapeutics, Plc's position in the market.
Akari Therapeutics (Nasdaq: AKTX), a late-stage biotechnology firm, reported its first-quarter 2024 financial results, announcing a net loss of $5.6 million and highlighting recent activities. The company entered into a definitive merger agreement with Peak Bio, anticipated to close in Q3 2024. The combined entity will prioritize Peak's ADC cancer therapeutic platform and Akari's PAS-nomacopan for Geographic Atrophy. A restructuring plan has commenced, reducing the workforce by 67% to cut operating costs. Akari issued $1 million in unsecured convertible notes to secure operational capital. Research and development expenses rose to $2.3 million, while general and administrative costs increased to $3.7 million, compared to the same period in 2023.
Summary: Akari Therapeutics, Plc announced the appointment of Samir R. Patel, M.D. as interim CEO, replacing Rachelle Jacques. Dr. Patel aims to complete the merger with Peak Bio, prioritize the company's portfolio, and advance its lead compound, nomacopan. The leadership changes are expected to bring cost savings through reduced clinical trial and infrastructure expenses.
Akari Therapeutics and Peak Bio have announced a joint portfolio prioritization plan following their merger, focusing on Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy. The companies aim to secure business development opportunities and funding while advancing these key programs.